Navigation Links
Codexis Appoints Singapore Laboratories Managing Director
Date:8/21/2007

REDWOOD CITY, Calif., Aug. 21 /PRNewswire/ -- Codexis, Inc., a private biotechnology company, today announced the appointment of Thomas Daussmann, Ph.D., to the new position of Vice President and Managing Director of Codexis Laboratories Singapore Pte. Ltd. CLS is the company's first facility in Asia. Dr. Daussmann will report to Alan Shaw, Ph.D., President and CEO.

"We are very pleased to name Dr. Daussmann to this important new position on the Codexis senior management team," Dr. Shaw said. "Thomas has built a strong track record of accomplishment as managing director of Codexis' Julich Chiral Solutions subsidiary, and he is a widely-respected scientist in the field of biocatalysis. He will play an equally critical role in building the company's Asian research and development presence."

Since 1999, Dr. Daussmann has served as managing director of Julich Chiral Solutions, (previously JFC-Julich Fine Chemicals), the Codexis enzyme and intermediates manufacturing facility in Germany. JFC was acquired by Codexis in 2005. Dr. Daussmann has authored or co-authored more than 25 scientific publication articles on biocatalytic manufacturing, and is named on numerous patent applications in the field. He received his bachelor's degree in biology from the University of Karlsruhe, his master's degree in biotechnology from the University of Kaiserslautern, and his Ph.D. degree in microbiology from the Research Centre in Julich (all in Germany). His doctoral study was conducted under the supervision of Professor Christian Wandrey, University of Bonn, a respected authority in biotechnology research.

Build-out has begun on the 20,000-square-foot research center in the Science Park III area of Singapore. It is scheduled to open this fall as an expansion of Codexis U.S. research and development operations. CLS will be able to house up to 80 research and operations personnel. Bio*One Capital Pte. Ltd. of Singapore led the Codexis Series D private financing round in August 2006.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit http://www.codexis.com

Contact: Justin Jackson, jjackson@burnsmc.com, Burns McClellan,

212-213-0006, or Lyn Christenson, lyn.christenson@codexis.com,

650-298-5368


'/>"/>
SOURCE Codexis, Inc.
Copyright©2007 PR Newswire.All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... CARLOS, Calif. , Jan. 23, 2017 /PRNewswire/ ... developing innovative treatments for neurodegenerative diseases and other ... has joined the company as Chief Medical Officer. ... translational and clinical development activities at Alkahest and ... Dr. Jackson most recently served as Executive Director ...
(Date:1/21/2017)... ... 20, 2017 , ... G&L Scientific Inc, a leading provider ... ), has announced the opening of new offices in Cambridge, Massachusetts, strengthening and ... This is the latest step in G&L’s expansion of its global clinical consulting ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... Jan. 21, 2017   Boston Biomedical , an ... to target cancer stemness pathways, today presented data from ... at the 2017 American Society of Clinical Oncology (ASCO) ... . In a Phase Ib/II study ... to inhibit cancer stemness pathways by targeting STAT3 – ...
Breaking Biology Technology:
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
Breaking Biology News(10 mins):